PURPOSE: Achieving a higher chemotherapy completion rate is associated with better outcomes in breast cancer patients. We examined the role of exercise and health-related fitness variables in predicting chemotherapy completion in early stage breast cancer patients. METHODS: We pooled data from two large, multicenter, exercise trials that obtained baseline (pre-chemotherapy) measures of exercise and health-related fitness in 543 breast cancer patients initiating adjuvant chemotherapy. Assessments included body composition, cardiovascular fitness, muscular strength, patient-reported physical functioning, and self-reported exercise behavior. Chemotherapy completion was assessed as the average relative dose intensity (RDI) for the originally planned regimen. We used logistic regression analyses with a two-sided p value of < 0.05 to estimate the associations between the predictors and an RDI of ≥ 85%. RESULTS: Overall, 432 of 543 (79.6%) breast cancer patients received an RDI of ≥ 85%. In logistic regression analyses adjusted for significant covariates, patients in the highest 20% vs. lowest 80% of absolute VO2peak were significantly more likely to complete ≥ 85% RDI (89.0% vs. 77.2%; ORadj 2.06, 95% CI 1.07-3.96, p = 0.031). Moreover, patients in the highest 80% vs. lowest 20% of absolute chest strength were significantly more likely to complete ≥ 85% RDI (81.5% vs. 71.4%; ORadj 1.80, 95% CI 1.09-2.98, p = 0.021). CONCLUSIONS: In these exploratory analyses, higher baseline (pre-chemotherapy) cardiovascular fitness and muscular strength were associated with higher rates of chemotherapy completion in early stage breast cancer patients. Aerobic and/or strength training interventions that increase cardiovascular fitness and muscular strength prior to chemotherapy for breast cancer may improve treatment tolerability and outcomes. CLINICAL TRIAL REGISTRATION: START: NCT00115713, June 24, 2005; CARE: NCT00249015, November 7, 2005 ( http://clinicaltrials.gov ).
PURPOSE: Achieving a higher chemotherapy completion rate is associated with better outcomes in breast cancer patients. We examined the role of exercise and health-related fitness variables in predicting chemotherapy completion in early stage breast cancer patients. METHODS: We pooled data from two large, multicenter, exercise trials that obtained baseline (pre-chemotherapy) measures of exercise and health-related fitness in 543 breast cancer patients initiating adjuvant chemotherapy. Assessments included body composition, cardiovascular fitness, muscular strength, patient-reported physical functioning, and self-reported exercise behavior. Chemotherapy completion was assessed as the average relative dose intensity (RDI) for the originally planned regimen. We used logistic regression analyses with a two-sided p value of < 0.05 to estimate the associations between the predictors and an RDI of ≥ 85%. RESULTS: Overall, 432 of 543 (79.6%) breast cancer patients received an RDI of ≥ 85%. In logistic regression analyses adjusted for significant covariates, patients in the highest 20% vs. lowest 80% of absolute VO2peak were significantly more likely to complete ≥ 85% RDI (89.0% vs. 77.2%; ORadj 2.06, 95% CI 1.07-3.96, p = 0.031). Moreover, patients in the highest 80% vs. lowest 20% of absolute chest strength were significantly more likely to complete ≥ 85% RDI (81.5% vs. 71.4%; ORadj 1.80, 95% CI 1.09-2.98, p = 0.021). CONCLUSIONS: In these exploratory analyses, higher baseline (pre-chemotherapy) cardiovascular fitness and muscular strength were associated with higher rates of chemotherapy completion in early stage breast cancer patients. Aerobic and/or strength training interventions that increase cardiovascular fitness and muscular strength prior to chemotherapy for breast cancer may improve treatment tolerability and outcomes. CLINICAL TRIAL REGISTRATION: START: NCT00115713, June 24, 2005; CARE: NCT00249015, November 7, 2005 ( http://clinicaltrials.gov ).
Entities:
Keywords:
Body composition; Breast cancer; Chemotherapy; Exercise; Physical fitness
Authors: Scott C Adams; Roanne J Segal; Donald C McKenzie; James R Vallerand; Andria R Morielli; John R Mackey; Karen Gelmon; Christine M Friedenreich; Robert D Reid; Kerry S Courneya Journal: Breast Cancer Res Treat Date: 2016-07-09 Impact factor: 4.872
Authors: Kerry S Courneya; Donald C McKenzie; John R Mackey; Karen Gelmon; Christine M Friedenreich; Yutaka Yasui; Robert D Reid; Diane Cook; Diana Jespersen; Carolyn Proulx; Lianne B Dolan; Cynthia C Forbes; Evyanne Wooding; Linda Trinh; Roanne J Segal Journal: J Natl Cancer Inst Date: 2013-10-22 Impact factor: 13.506
Authors: Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Jacobien M Kieffer; Laurien M Buffart; Marianne de Maaker-Berkhof; Epie Boven; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Aart van Bochove; Vera Lustig; Simone M van den Heiligenberg; Carolien H Smorenburg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson Journal: J Clin Oncol Date: 2015-04-27 Impact factor: 44.544
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Lu Zhang; Qingzhao Yu; Xiao-Cheng Wu; Mei-Chin Hsieh; Michelle Loch; Vivien W Chen; Elizabeth Fontham; Tekeda Ferguson Journal: Breast Cancer Res Treat Date: 2018-01-24 Impact factor: 4.872
Authors: Mark D Eisner; Paul D Blanc; Steve Sidney; Edward H Yelin; Phenius V Lathon; Patricia P Katz; Irina Tolstykh; Lynn Ackerson; Carlos Iribarren Journal: Respir Res Date: 2007-01-29